Skip to main content

Table 3 Factors associated with chemotherapy-induced Dose-Limiting Neurotoxicity (DLN)

From: Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

Characteristicsa DLNs No DLN Univariate analysis Multivariate analysisd
(n = 19) (n = 26) p value HR [95% CI] p value
Maximum handgrip strength, mean ± SD 29.1 ± 10.3 28.5 ± 9.1 0.64   
Dynapenia    0.13   0.02
No 12 (63.2) 22 (84.6)   1  
Yes 7 (36.8) 4 (15.4)   3.5 [1.3; 9.8]  
Age, mean ± SD 65.9 ± 11.5 66.5 ± 13.1 0.89   
ECOG PS    0.04   0.03
 0 8 (42.1) 4 (15.4)   1  
 1 or 2 11 (57.9) 22 (84.6)   0.4 [0.2; 0.9]  
mGPS b    0.39   
0 8 (50.0) 9 (39.1)    
1 8 (50.0) 9 (39.1)    
2 0 (0.0) 2 (21.7)    
Primary Tumor location    0.02   0.01
 Stomach – Biliary tract – Small Intestine 6 (31.6) 1 (4.2)   3.6 [1.3; 10.0]  
 Other location 13 (68.4) 23 (95.8)   1  
Stage    0.49   
 Local 10 (52.6) 10 (38.5)    
 Locally advanced 1 (5.3) 5 (19.2)    
 Metastatic 8 (42.1) 11 (42.3)    
BMI, mean ± SD, kg/m2 23.9 ± 3.4 22.8 ± 4.5 0.048   
Overweight, No. (%)c    0.02   
 Yes 9 (47.4) 5 (19.2)    
 No 10 (52.6) 21 (80.8)    
  1. SD standard deviation, HR Hazard Ratio, BMI body mass index, mGPS modified Glasgow Prognostic Score, ECOG PS Eastern Cooperative Oncology Group Criteria Performance Status
  2. aData are expressed as No (%) unless otherwise indicated
  3. b6 missing data
  4. coverweight was defined as BMI > 25 kg/m2
  5. dfour variables were included in multivariate analysis: dynapenia, ECOG PS, overweight and tumoral location, neurotoxic chemotherapy was not included in multivariate analysis because of one strata has no event (convergence wasn’t satisfied)